Quinn Anthony G. 4
4 · Generation Bio Co. · Filed Feb 9, 2026
Research Summary
AI-generated summary of this filing
Generation Bio (GBIO) Director Anthony G. Quinn Sells Shares in Merger
What Happened
Anthony G. Quinn, a director, disposed of a total of 57,331 Generation Bio (GBIO) shares on February 9, 2026 in connection with a change-of-control transaction (tender offer and merger). Each tendered share was exchanged for $4.2913 in cash (total cash ≈ $246,025) plus one non-tradeable contingent value right (CVR) per share; the CVRs have an estimated maximum contingent consideration of $25.01 per CVR. Several reported dispositions labeled as "to the issuer" reflect the merger treatment of outstanding options (see details below).
Key Details
- Transaction date: February 9, 2026 (Effective Time of Merger). Filing date: February 9, 2026.
- Cash price per share: $4.2913; total shares disposed: 57,331; estimated cash received ≈ $246,025.
- Additional consideration: one non-tradeable CVR per share; estimated maximum contingent consideration of $25.01 per CVR (contingent, not guaranteed).
- Some dispositions were derivative-related (options): in‑the‑money options were cashed out under the merger formula (Cash Amount minus option exercise price times underlying shares); options with exercise price ≥ Cash Amount were cancelled for no consideration.
- Securities were held directly by the Quinn Family Irrevocable Trust of 2021 (Quinn Family Trust). The Form 4 notes the trust as the direct holder. The report does not specify post-transaction share balance.
- This was a merger/tender-offer disposition (not an open-market sale); filing appears timely (same-day).
Context
These sales were part of a contractual change-of-control process (tender offer and subsequent merger), not routine open‑market selling—shares were exchanged per the Merger Agreement and certain options were automatically cashed out or cancelled. CVRs are contingent rights and are non-tradeable; any additional payment depends on future events per the CVR agreement.
Insider Transaction Report
Form 4Exit
Quinn Anthony G.
Director
Transactions
- Disposition from Tender
Common Stock
[F1][F2]2026-02-09−29,928→ 0 total - Disposition from Tender
Common Stock
[F1][F2][F3]2026-02-09−7,283→ 0 total(indirect: By Trust) - Disposition to Issuer
Stock Option (right to buy)
[F4]2026-02-09−3,000→ 0 totalExercise: $3.87→ Common Stock (3,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
[F5]2026-02-09−5,200→ 0 totalExercise: $190.00→ Common Stock (5,200 underlying) - Disposition to Issuer
Stock Option (right to buy)
[F5]2026-02-09−1,500→ 0 totalExercise: $265.90→ Common Stock (1,500 underlying) - Disposition to Issuer
Stock Option (right to buy)
[F5]2026-02-09−1,920→ 0 totalExercise: $61.90→ Common Stock (1,920 underlying) - Disposition to Issuer
Stock Option (right to buy)
[F5]2026-02-09−2,500→ 0 totalExercise: $48.30→ Common Stock (2,500 underlying) - Disposition to Issuer
Stock Option (right to buy)
[F5]2026-02-09−6,000→ 0 totalExercise: $33.20→ Common Stock (6,000 underlying)
Footnotes (5)
- [F1]Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"),
- [F2](continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
- [F3]The securities are directly held by the Quinn Family Irrevocable Trust of 2021 (the "Quinn Family Trust"), formerly the Spousal Lifetime Access Trust. Anthony G. Quinn is the settlor of the Quinn Family Trust, M. Clare Quinn is the trustee for the Quinn Family Trust and the Quinn Family Trust is for the benefit of M. Clare Quinn, Emma, Richard, and Charles Quinn.
- [F4]Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time.
- [F5]Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Signature
/s/ Shawna-Gay White, Attorney-in-Fact|2026-02-09